Trial Profile
Impact of Combined Medication and Behavioral Treatment in Young Children With Comorbid ASD and ADHD
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Amphetamines (Primary)
- Indications Attention-deficit hyperactivity disorder; Pervasive child development disorders
- Focus Therapeutic Use
- 17 Aug 2021 Status changed from recruiting to suspended.
- 07 Feb 2020 Planned number of patients changed from 78 to 48.
- 07 Feb 2020 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.